Evidence map›Paper›PMID 37964635›Full record

ArticleBMB reports2024

MMPP is a novel VEGFR2 inhibitor that suppresses angiogenesis via VEGFR2/AKT/ERK/NF-κB pathway.

Na-Yeon Kim, Hyo-Min Park, Jae-Young Park, Uijin Kim, Ha Youn Shin, Hee Pom Lee, Jin Tae Hong, Do-Young Yoon

Open access · goldAbstract readNews
PubMed Full text at PMC
In one paragraph

Article in BMB reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Na-Yeon KimDepartment of Bioscience and Biotechnology, Konkuk University, Seoul 05029, Korea.
Hyo-Min ParkDepartment of Bioscience and Biotechnology, Konkuk University, Seoul 05029, Korea.
Jae-Young ParkDepartment of Bioscience and Biotechnology, Konkuk University, Seoul 05029, Korea.
Uijin KimDepartment of Biomedical Science and Engineering, Konkuk University, Seoul 05029, Korea.
Ha Youn ShinDepartment of Biomedical Science and Engineering, Konkuk University, Seoul 05029, Korea.
Hee Pom LeeCollege of Pharmacy & Medical Research Center, Chungbuk National University, Cheongju 28160, Korea.
Jin Tae HongCollege of Pharmacy & Medical Research Center, Chungbuk National University, Cheongju 28160, Korea.
Do-Young YoonDepartment of Bioscience and Biotechnology, Konkuk University, Seoul 05029, Korea.
Konkuk University · KRChungbuk National University · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Many types of cancer are associated with excessive angiogenesis. Anti-angiogenic treatment is an effective strategy for treating solid cancers. This study aimed to demonstrate the inhibitory effects of (E)-2-methoxy-4-(3-(4-methoxyphenyl) prop-1-en-1-yl) phenol (MMPP) in VEGFA-induced angiogenesis. The results indicated that MMPP effectively suppressed various angiogenic processes, such as cell migration, invasion, tube formation, and sprouting of new vessels in human umbilical vein endothelial cells (HUVECs) and mouse aortic ring. The inhibitory mechanism of MMPP on angiogenesis involves targeting VEGFR2. MMPP showed high binding affinity for the VEGFR2 ATP-binding domain. Additionally, MMPP improved VEGFR2 thermal stability and inhibited VEGFR2 kinase activity, suppressing the downstream VEGFR2/AKT/ERK pathway. MMPP attenuated the activation and nuclear translocation of NF-κB, and it downregulated NF-κB target genes such as VEGFA, VEGFR2, MMP2, and MMP9. Furthermore, conditioned medium from MMPP-treated breast cancer cells effectively inhibited angiogenesis in endothelial cells. These results suggested that MMPP had great promise as a novel VEGFR2 inhibitor with potent anti-angiogenic properties for cancer treatment via VEGFR2/AKT/ERK/NF-κB signaling pathway. [BMB Reports 2024; 57(5): 244-249].

Indexed as

Angiogenesis InhibitorsCell MovementHuman Umbilical Vein Endothelial CellsNeovascularization, PathologicNF-kappa BProto-Oncogene Proteins c-aktSignal TransductionVascular Endothelial Growth Factor Receptor-2AngiogenesisAnimalsHumansMAP Kinase Signaling SystemMicePhenolsAngiogenesis InhibitorsKDR protein, humanNF-kappa BPhenolsProto-Oncogene Proteins c-aktVascular Endothelial Growth Factor Receptor-2

Identifiers

PMID37964635
PMCPMC11139683
OpenAlexW4388636778

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.